Page 1

IDEXX FOR IMMEDIATE RELEASE Contact : John Ravis , Investor Relations , 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results Achieves reported revenue growth of 24 % and organic growth of 21 % , driven by CAG Diagnostics recurring revenue growth of 27 % as reported and 23 % organic Delivers EPS of $ 2.35 , representing 82 % growth as reported and 73 % on a comparable basis Increases 2021 revenue guidance to $ 3,105 million - $ 3,160 million , reflecting higher expectations for reported growth of 14.5 % -16.5 % and organic growth of 13 % - 15 % , supported by projected CAG Diagnostics recurring revenue growth of 16 % - 17.5 % as reported and 14.5 % -16 % organic Raises 2021 EPS outlook to $ 7.88 - $ 8.18 , reflecting expectations for 1.5 % higher organic revenue growth and targeted operating margin improvement of 270 - 320 basis points as reported and 150 - 200 basis points on a comparable basis WESTBROOK , Maine , May 4 , 2021- IDEXX Laboratories , Inc. ( NASDAQ : IDXX ) , a global leader in veterinary diagnostics , veterinary practice software and water microbiology testing , today announced first quarter results , as well as an update on U.S. companion animal diagnostics market trends . First Quarter Results The Company reports revenues of $ 778 million for the first quarter of 2021 , an increase of 24 % as reported and 21 % organic . First quarter results were driven by Companion Animal Group ( " CAG " ) Diagnostics recurring revenue growth of 27 % reported and 23 % organic , reflecting continued high gains in the U.S. and internationally , as well as 31 % reported and 27 % organic growth in CAG Diagnostics capital instrument revenue . Overall revenue growth was also supported by 15 % reported and 9 % organic revenue growth in the Livestock , Poultry and Dairy ( " LPD " ) business and by approximately 1 % of growth benefit from revenues associated with OPTI Medical Systems COVID - 19 human PCR testing . Earnings per diluted share ( " EPS " ) of $ 2.35 for the first quarter was supported by strong operating margin gains , reflecting benefits from high CAG Diagnostics recurring revenue growth and favorable comparisons to higher prior year pre - COVID - 19 operating expense levels . Overall operating margins improved 880 basis points as reported compared to prior year levels and 830 basis points on a comparable basis . EPS results also benefited from a higher than expected $ 0.17 per share in tax benefits from share - based compensation . " The IDEXX team delivered exceptional performance in the first quarter , reflecting continued robust demand for companion animal healthcare globally , supported by our innovation and direct commercial engagement , " said Jay Mazelsky , the Company's President and Chief Executive Officer . " We achieved 32 % year - over - year growth in CAG premium instrument placements , as our customers look ahead to